MaxCyte (MXCT) stock

Cell engineering tools , market cap $135M

Cell engineering technology for cell therapies

Worth $135M

Pre-market

$1.27

+0.79%

Close $1.26 -3.82%

As of 8:53 AM ET pre-market, delayed 15+ min · Live for Pro members

Why is MXCT down?

Down 27% from Oct 29 to Nov 6 while the S&P 500 fell 4%.

MaxCyte fell 27% from Oct 29 to Nov 6 while biotech stocks fell a median 3%: it trailed its group by 24 points.

Sources: Price history, Nov 6, 2026

Tell me next time MXCT moves

Free account, no card. An optional alert when MXCT moves or its score changes.

Or see it live, free until tomorrow morning. No account.

The other side, the timeline, and its peers, for Pro members.

Quality Score

-3

Poor

In its industry

#177of 281

Biotech

Checks firing

2of 14

Trending up

From 52-week high

-30.2%

under its best in a year

MXCT's Quality Score fell 2 points on Fri, Nov 6, to -3. Its price fell below its average of the last 200 days.

See MXCT's 14 chart checksSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on MXCT

Key facts on MXCT
Since its Nov 2021 high	Down 90% a $19.1M loss → a $35.6M loss a year
Latest filing	8-K, Oct 14 Reported its quarterly results

1 more reason behind MXCT's -3, free with an account →4 more reasons behind MXCT's -3, for Pro members.

MXCT in the news

ReportReports tomorrow, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +14.1% on average. Past reports ›

Big story

Guidance

MaxCyte raises 2026 revenue guidance on strong Q3 results By Investing.com

Reported by investing.com uk · covered by 9 outlets

Get an alert on MXCT's next big story →

What's next

Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

MXCT catalysts

Coming up

After its last 4 reports it closed +14.1% on average, higher 3 of 4 times.

Why MXCT scores -3

Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. MXCT scores -3 today, against a median of 3 over its last 20 recorded sessions.

+2Chart checks 2 of 14 firing right now, one point each
−2Volatility moves 9.9% a day on a $36M loss over four quarters, with no positive free cash flowA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

Long-term trend subtracts
Run-up adds
Size subtracts
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Profit, Dilution, Persistence, and News.

What every line is worth, and the reason behind it, on MXCT and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:53 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How MXCT ranks in Biotech

MXCT is #177 of 281 by Quality Score.

How MXCT ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	MPLTMapLight Therapeutics		Open for its score
	MRNAModerna		Open for its score
	NAGENiagen Bioscience		Open for its score
	NAMSNewAmsterdam Pharma		Open for its score
177	MXCTMaxCyte	2/14	-3

When does MXCT report earnings, and what happens after?

Reports Tue Nov 10, after the close (tomorrow). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What MXCT reported on Oct 14, 2026

The quarter

The figures are not read from the release yet.

The filing on EDGAR

Where the sales came from

MXCT's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year
Revenue	$34Mraised

Figures as filed (SEC filing, Oct 14)

2 more outlook lines, for Pro members.

The numbers

Market value: $135M; today
Sales: $31.1M; down 13.2% on the year
Free cash flow: -$23.6M; last 12 months

Its share count grew 8.9% a year over 5 years.

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on MXCT: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+24.1%+9.4%+29.6%

May 12Aug 12Oct 14

Reported	When	Gap	Reaction	5 days
Oct 14, 2026Before open	Before open	+27.0%	+29.6%	+48.3%
Aug 12, 2026After close	After close	-7.9%	+9.4%	+9.4%
May 12, 2026After close	After close	+14.3%	+24.1%	+26.5%

MXCT closed higher after 3 of its last 4 reports.

All 4 reports, and MXCT's Quality Score going into each

Everyone reporting earnings this week

MXCT sales and profit by year

Sales and profit by year

Sales grew in three of the last six years, to $33M in 2025. It lost money in each of the seven years.

MXCT has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on MXCT, and all 14 on every stock.Get in free →

MXCT RSI on Nov 6: 44.0, above its 50-day and 200-day averages

Not scored

RSI 44.0, MACD below signal, above both averages. Not scored.13 readings

The deep dive on MXCT

What it does and how it makes money4 findingsAn operating loss of $51.9M in fiscal 2025, on $33.0M of sales.Annual report, filed Mar 25, 2026"Protection over our instruments and related control and process elements is estimated to last through at least 2028, and protection for our electroporation applications is estimated to extend through at least 2037, subject to jurisdiction-specific patent term rules and other factors." (10-K for fiscal 2025)SEC filing · Mar 25, 2026
Where it stands3 findingsFor Pro members3 findings on where MXCT stands: its cash, debt, and share count, for Pro members
What changed in its filings2 findingsOne customer made up 26% of its revenue in fiscal 2025, up from 23% in fiscal 2024.SEC filing · Mar 25, 2026Backlog rose 30% in a year, to $427K on Jun 30, 2026 from $328K: sales under contract, not yet delivered.Filed figures, Jun 30, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades MXCT, for Pro members

7 more findings on MXCT, each with its source, for Pro members.

MXCT's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Maher MasoudPresident and CEO · no trades on file
Douglas J. SwirskyChief Financial Officer · 1 trade
Parmeet AhujaChief Financial Officer · no trades on file
Cynthia CollinsDirector · no trades on file
John Joseph JohnstonDirector · no trades on file
Patrick J. BalthropDirector · no trades on file
Rekha HemrajaniDirector · no trades on file
Richard DouglasDirector · no trades on file

3 more officers and directors file at MXCT.

See insider trades by person

Which ETFs hold MXCT?

In ETFs: MXCT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About MaxCyte

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

91 employeesRockville, MDmaxcyte.com

What MaxCyte says it competes with

“The life sciences market is highly competitive and dynamic, reflecting rapid technological evolution and continually evolving customer requirements.”

From its annual report, SEC filing · Mar 25, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on MXCT and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn MXCT's score around: 8 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

See MXCT's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: MXCT's Quality Score is -3 (Poor), #177 of 281 in Biotech.

What does MXCT's Quality Score say?

MXCT scores -3 today, which Breakaway calls Poor. It is #177 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 27% from Oct 29 to Nov 6 while the S&P 500 fell 4%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MXCT's Quality Score?

MXCT scores -3 today, which Breakaway calls Poor (below zero). That is #177 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MXCT's -3.

When does MXCT report earnings?

Reports Tue Nov 10, after the close, a date the company confirmed. MXCT closed higher after 3 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.